Literature DB >> 23979112

Analysis of free fractions for chiral drugs using ultrafast extraction and multi-dimensional high-performance affinity chromatography.

Xiwei Zheng1, Michelle J Yoo, David S Hage.   

Abstract

A multi-dimensional chromatographic approach was developed to measure the free fractions of drug enantiomers in samples that also contained a binding protein or serum. This method, which combined ultrafast affinity extraction with a chiral stationary phase, was demonstrated using the drug warfarin and the protein human serum albumin.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23979112      PMCID： PMC3812820          DOI： 10.1039/c3an01315d

Source DB:  PubMed          Journal:  Analyst        ISSN： 0003-2654            Impact factor:   4.616


  13 in total

1.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

2.  Atomic structure and chemistry of human serum albumin.

Authors:  X M He; D C Carter
Journal:  Nature       Date:  1992-07-16       Impact factor: 49.962

3.  Analysis of free drug fractions using near-infrared fluorescent labels and an ultrafast immunoextraction/displacement assay.

Authors:  Corey M Ohnmacht; John E Schiel; David S Hage
Journal:  Anal Chem       Date:  2006-11-01       Impact factor: 6.986

Review 4.  Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding.

Authors:  F Hervé; S Urien; E Albengres; J C Duché; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

5.  Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determination of free fractions of phenobarbital and phenytoin.

Authors:  J W Melten; A J Wittebrood; H J Willems; G H Faber; J Wemer; D B Faber
Journal:  J Pharm Sci       Date:  1985-06       Impact factor: 3.534

6.  Analysis of free hormone fractions by an ultrafast immunoextraction/displacement immunoassay: studies using free thyroxine as a model system.

Authors:  William Clarke; John E Schiel; Annette Moser; David S Hage
Journal:  Anal Chem       Date:  2005-03-15       Impact factor: 6.986

7.  Analysis of free drug fractions by ultrafast immunoaffinity chromatography.

Authors:  W Clarke; A R Chowdhuri; D S Hage
Journal:  Anal Chem       Date:  2001-05-15       Impact factor: 6.986

8.  Optimization of human serum albumin monoliths for chiral separations and high-performance affinity chromatography.

Authors:  Erika L Pfaunmiller; Mahli Hartmann; Courtney M Dupper; Sony Soman; David S Hage
Journal:  J Chromatogr A       Date:  2012-09-10       Impact factor: 4.759

9.  Development of an affinity silica monolith containing human serum albumin for chiral separations.

Authors:  Rangan Mallik; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2007-03-24       Impact factor: 3.935

10.  Chiral separation mechanisms in protein-based HPLC columns. 1. Thermodynamic studies of (R)- and (S)-warfarin binding to immobilized human serum albumin.

Authors:  B Loun; D S Hage
Journal:  Anal Chem       Date:  1994-11-01       Impact factor: 6.986
View more
  20 in total

1.  Analysis of Hormone-Protein Binding in Solution by Ultrafast Affinity Extraction: Interactions of Testosterone with Human Serum Albumin and Sex Hormone Binding Globulin.

Authors:  Xiwei Zheng; Cong Bi; Marissa Brooks; David S Hage
Journal:  Anal Chem       Date:  2015-10-27       Impact factor: 6.986

Review 2.  High performance affinity chromatography and related separation methods for the analysis of biological and pharmaceutical agents.

Authors:  Chenhua Zhang; Elliott Rodriguez; Cong Bi; Xiwei Zheng; Doddavenkatana Suresh; Kyungah Suh; Zhao Li; Fawzi Elsebaei; David S Hage
Journal:  Analyst       Date:  2018-01-15       Impact factor: 4.616

Review 3.  Analysis of stereoselective drug interactions with serum proteins by high-performance affinity chromatography: A historical perspective.

Authors:  Zhao Li; David S Hage
Journal:  J Pharm Biomed Anal       Date:  2017-01-11       Impact factor: 3.935

Review 4.  Affinity chromatography: A review of trends and developments over the past 50 years.

Authors:  Elliott L Rodriguez; Saumen Poddar; Sazia Iftekhar; Kyungah Suh; Ashley G Woolfork; Susan Ovbude; Allegra Pekarek; Morgan Walters; Shae Lott; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2020-08-14       Impact factor: 3.205

5.  Characterization of solution-phase drug-protein interactions by ultrafast affinity extraction.

Authors:  Sandya R Beeram; Xiwei Zheng; Kyungah Suh; David S Hage
Journal:  Methods       Date:  2018-03-03       Impact factor: 3.608

6.  Analysis of free drug fractions in human serum by ultrafast affinity extraction and two-dimensional affinity chromatography.

Authors:  Xiwei Zheng; Maria Podariu; Ryan Matsuda; David S Hage
Journal:  Anal Bioanal Chem       Date:  2015-10-13       Impact factor: 4.142

7.  Chromatographic studies of drug interactions with alpha1-acid glycoprotein by ultrafast affinity extraction and peak profiling.

Authors:  Sandya Beeram; Cong Bi; Xiwei Zheng; David S Hage
Journal:  J Chromatogr A       Date:  2017-03-23       Impact factor: 4.759

Review 8.  Kinetic analysis of drug-protein interactions by affinity chromatography.

Authors:  Cong Bi; Sandya Beeram; Zhao Li; Xiwei Zheng; David S Hage
Journal:  Drug Discov Today Technol       Date:  2015-10-08

9.  Analysis of free drug fractions by ultrafast affinity extraction: interactions of sulfonylurea drugs with normal or glycated human serum albumin.

Authors:  Xiwei Zheng; Ryan Matsuda; David S Hage
Journal:  J Chromatogr A       Date:  2014-10-31       Impact factor: 4.759

Review 10.  Analysis of biomolecular interactions using affinity microcolumns: a review.

Authors:  Xiwei Zheng; Zhao Li; Sandya Beeram; Maria Podariu; Ryan Matsuda; Erika L Pfaunmiller; Christopher J White; NaTasha Carter; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-01-27       Impact factor: 3.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.